PS-068 Analysis and improvement of prescription and administration in hospital transitions

BackgroundAnticholinergic drugs (AchD) are often prescribed in elderly patients. They may increase cognitive and functional disorders, decrease the effects of anticholinesterase drugs (AcsD) and cause other adverse reactions, especially in Alzheimer’s disease (AD).PurposeTo analyse atropinic burden...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A257-A257
Hauptverfasser: Vilarrasa, L Canadell, Broseta, PA López, Parada, L Sánchez, Marqués, M Martín, López, A de Dios, Sirgo, G, Rodriguez, A, Esteban, F, Olona, M, Bodí, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A257
container_issue Suppl 1
container_start_page A257
container_title European journal of hospital pharmacy. Science and practice
container_volume 24
creator Vilarrasa, L Canadell
Broseta, PA López
Parada, L Sánchez
Marqués, M Martín
López, A de Dios
Sirgo, G
Rodriguez, A
Esteban, F
Olona, M
Bodí, M
description BackgroundAnticholinergic drugs (AchD) are often prescribed in elderly patients. They may increase cognitive and functional disorders, decrease the effects of anticholinesterase drugs (AcsD) and cause other adverse reactions, especially in Alzheimer’s disease (AD).PurposeTo analyse atropinic burden (AB) using various scales in order to quantify the associated risk and to identify the most prescribed AchD in hospitalised patients with AD.Material and methodsBibliographic search in Pubmed using as the main terms ‘atropinic’, ‘anticholinergic’ and ‘Alzheimer’. This was a retrospective study performed from May 2015 to July 2016. APD prescription software and DIRAYA database were used to obtain prescription, demographic and patient data. 9 scales (7 of them validated) were chosen to identify drugs with AB and to quantify them.Results49 hospitalised patients were studied, 26 men and 23 women, with an average age of 81.82±7.13 years. There were 6 deaths during hospitalisation (12.25%). All patients were receiving 1 or more AcsD to treat AD. 4 patients (8%) were not receiving AchD during hospitalisation while the rest were taking 1 or more AchD: 16 patients 1 drug (32.65%), 19 patients 2 drugs (38.77%), 5 patients 3 drugs (10.20%) and 3 patients were taking 4 AchD (6.12%). Only 1 patient was not at risk, 4 were at intermediate–low risk and 44 were at high risk according at least to 1 scale (89.79%). 28 patients were at high risk in 5 or more scales (57.14%). Psychotropic drugs with anticholinergic effects were prescribed in 28 patient (57%). Most prescribed drugs were haloperidol (11 patients, 22.45%), quetiapine (14 patients, 28.57%) and ipratropium (7 patients, 14.28%).ConclusionIt is common practice to prescribe AchD in elderly hospitalised patients with AD. Cumulative administration of these drugs makes this fragile type of patients especially vulnerable to anticholinergic adverse effects.References and/or acknowledgementsVillalba-Moreno AM, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr2015;62:1–8.Montrastuc F, et al. Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French pharmacovigilance database. EJC Pharmacology 2015;71./:891–5.Grey SL, et al. Cumulative use of strong anticholinergic medications and incident dementia. JAMA Intern Med 2015;175:401–7.No conflict of interest
doi_str_mv 10.1136/ejhpharm-2017-000640.574
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552765279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4317856621</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1009-2a6a464e9a9f727c922b25c7bc0d0eb6f7f99b0d92003e38e86a9cf99c16d0883</originalsourceid><addsrcrecordid>eNp9kM9KAzEQh4MoWGrfYcFz6iTZTTbHUvwHBQX1JoRkN0tTutk12Qq9efFFfRKzrXr0ECZ882OY-RDKCMwJYfzKbtb9WocWUyACAwDPYV6I_ARNKOQCS8nz079_wc_RLEZnoGCslDmTE_T6-ISBl18fnwuvt_voYqZ9nbm2D927ba0fsq7J-mBjFVw_uM4f-rpunXdxCPqAnM_WXezdoLdZYj66EccLdNbobbSznzpFLzfXz8s7vHq4vV8uVtgQAImp5jrnuZVaNoKKSlJqaFEJU0EN1vBGNFIaqCUFYJaVtuRaVolVhNdQlmyKLo9z09JvOxsHtel2Id0TFS0KKnh68r8UKQUblRQ8pdgxZdqN6oNrddgrAmr0rX59q9G3OvpWyTf7BnnUdnA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1873338956</pqid></control><display><type>article</type><title>PS-068 Analysis and improvement of prescription and administration in hospital transitions</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Vilarrasa, L Canadell ; Broseta, PA López ; Parada, L Sánchez ; Marqués, M Martín ; López, A de Dios ; Sirgo, G ; Rodriguez, A ; Esteban, F ; Olona, M ; Bodí, M</creator><creatorcontrib>Vilarrasa, L Canadell ; Broseta, PA López ; Parada, L Sánchez ; Marqués, M Martín ; López, A de Dios ; Sirgo, G ; Rodriguez, A ; Esteban, F ; Olona, M ; Bodí, M</creatorcontrib><description>BackgroundAnticholinergic drugs (AchD) are often prescribed in elderly patients. They may increase cognitive and functional disorders, decrease the effects of anticholinesterase drugs (AcsD) and cause other adverse reactions, especially in Alzheimer’s disease (AD).PurposeTo analyse atropinic burden (AB) using various scales in order to quantify the associated risk and to identify the most prescribed AchD in hospitalised patients with AD.Material and methodsBibliographic search in Pubmed using as the main terms ‘atropinic’, ‘anticholinergic’ and ‘Alzheimer’. This was a retrospective study performed from May 2015 to July 2016. APD prescription software and DIRAYA database were used to obtain prescription, demographic and patient data. 9 scales (7 of them validated) were chosen to identify drugs with AB and to quantify them.Results49 hospitalised patients were studied, 26 men and 23 women, with an average age of 81.82±7.13 years. There were 6 deaths during hospitalisation (12.25%). All patients were receiving 1 or more AcsD to treat AD. 4 patients (8%) were not receiving AchD during hospitalisation while the rest were taking 1 or more AchD: 16 patients 1 drug (32.65%), 19 patients 2 drugs (38.77%), 5 patients 3 drugs (10.20%) and 3 patients were taking 4 AchD (6.12%). Only 1 patient was not at risk, 4 were at intermediate–low risk and 44 were at high risk according at least to 1 scale (89.79%). 28 patients were at high risk in 5 or more scales (57.14%). Psychotropic drugs with anticholinergic effects were prescribed in 28 patient (57%). Most prescribed drugs were haloperidol (11 patients, 22.45%), quetiapine (14 patients, 28.57%) and ipratropium (7 patients, 14.28%).ConclusionIt is common practice to prescribe AchD in elderly hospitalised patients with AD. Cumulative administration of these drugs makes this fragile type of patients especially vulnerable to anticholinergic adverse effects.References and/or acknowledgementsVillalba-Moreno AM, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr2015;62:1–8.Montrastuc F, et al. Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French pharmacovigilance database. EJC Pharmacology 2015;71./:891–5.Grey SL, et al. Cumulative use of strong anticholinergic medications and incident dementia. JAMA Intern Med 2015;175:401–7.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2017-000640.574</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Alzheimer's disease ; Patients ; Prescription drugs</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A257-A257</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 (c) 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Vilarrasa, L Canadell</creatorcontrib><creatorcontrib>Broseta, PA López</creatorcontrib><creatorcontrib>Parada, L Sánchez</creatorcontrib><creatorcontrib>Marqués, M Martín</creatorcontrib><creatorcontrib>López, A de Dios</creatorcontrib><creatorcontrib>Sirgo, G</creatorcontrib><creatorcontrib>Rodriguez, A</creatorcontrib><creatorcontrib>Esteban, F</creatorcontrib><creatorcontrib>Olona, M</creatorcontrib><creatorcontrib>Bodí, M</creatorcontrib><title>PS-068 Analysis and improvement of prescription and administration in hospital transitions</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundAnticholinergic drugs (AchD) are often prescribed in elderly patients. They may increase cognitive and functional disorders, decrease the effects of anticholinesterase drugs (AcsD) and cause other adverse reactions, especially in Alzheimer’s disease (AD).PurposeTo analyse atropinic burden (AB) using various scales in order to quantify the associated risk and to identify the most prescribed AchD in hospitalised patients with AD.Material and methodsBibliographic search in Pubmed using as the main terms ‘atropinic’, ‘anticholinergic’ and ‘Alzheimer’. This was a retrospective study performed from May 2015 to July 2016. APD prescription software and DIRAYA database were used to obtain prescription, demographic and patient data. 9 scales (7 of them validated) were chosen to identify drugs with AB and to quantify them.Results49 hospitalised patients were studied, 26 men and 23 women, with an average age of 81.82±7.13 years. There were 6 deaths during hospitalisation (12.25%). All patients were receiving 1 or more AcsD to treat AD. 4 patients (8%) were not receiving AchD during hospitalisation while the rest were taking 1 or more AchD: 16 patients 1 drug (32.65%), 19 patients 2 drugs (38.77%), 5 patients 3 drugs (10.20%) and 3 patients were taking 4 AchD (6.12%). Only 1 patient was not at risk, 4 were at intermediate–low risk and 44 were at high risk according at least to 1 scale (89.79%). 28 patients were at high risk in 5 or more scales (57.14%). Psychotropic drugs with anticholinergic effects were prescribed in 28 patient (57%). Most prescribed drugs were haloperidol (11 patients, 22.45%), quetiapine (14 patients, 28.57%) and ipratropium (7 patients, 14.28%).ConclusionIt is common practice to prescribe AchD in elderly hospitalised patients with AD. Cumulative administration of these drugs makes this fragile type of patients especially vulnerable to anticholinergic adverse effects.References and/or acknowledgementsVillalba-Moreno AM, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr2015;62:1–8.Montrastuc F, et al. Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French pharmacovigilance database. EJC Pharmacology 2015;71./:891–5.Grey SL, et al. Cumulative use of strong anticholinergic medications and incident dementia. JAMA Intern Med 2015;175:401–7.No conflict of interest</description><subject>Alzheimer's disease</subject><subject>Patients</subject><subject>Prescription drugs</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM9KAzEQh4MoWGrfYcFz6iTZTTbHUvwHBQX1JoRkN0tTutk12Qq9efFFfRKzrXr0ECZ882OY-RDKCMwJYfzKbtb9WocWUyACAwDPYV6I_ARNKOQCS8nz079_wc_RLEZnoGCslDmTE_T6-ISBl18fnwuvt_voYqZ9nbm2D927ba0fsq7J-mBjFVw_uM4f-rpunXdxCPqAnM_WXezdoLdZYj66EccLdNbobbSznzpFLzfXz8s7vHq4vV8uVtgQAImp5jrnuZVaNoKKSlJqaFEJU0EN1vBGNFIaqCUFYJaVtuRaVolVhNdQlmyKLo9z09JvOxsHtel2Id0TFS0KKnh68r8UKQUblRQ8pdgxZdqN6oNrddgrAmr0rX59q9G3OvpWyTf7BnnUdnA</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Vilarrasa, L Canadell</creator><creator>Broseta, PA López</creator><creator>Parada, L Sánchez</creator><creator>Marqués, M Martín</creator><creator>López, A de Dios</creator><creator>Sirgo, G</creator><creator>Rodriguez, A</creator><creator>Esteban, F</creator><creator>Olona, M</creator><creator>Bodí, M</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201703</creationdate><title>PS-068 Analysis and improvement of prescription and administration in hospital transitions</title><author>Vilarrasa, L Canadell ; Broseta, PA López ; Parada, L Sánchez ; Marqués, M Martín ; López, A de Dios ; Sirgo, G ; Rodriguez, A ; Esteban, F ; Olona, M ; Bodí, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1009-2a6a464e9a9f727c922b25c7bc0d0eb6f7f99b0d92003e38e86a9cf99c16d0883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer's disease</topic><topic>Patients</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vilarrasa, L Canadell</creatorcontrib><creatorcontrib>Broseta, PA López</creatorcontrib><creatorcontrib>Parada, L Sánchez</creatorcontrib><creatorcontrib>Marqués, M Martín</creatorcontrib><creatorcontrib>López, A de Dios</creatorcontrib><creatorcontrib>Sirgo, G</creatorcontrib><creatorcontrib>Rodriguez, A</creatorcontrib><creatorcontrib>Esteban, F</creatorcontrib><creatorcontrib>Olona, M</creatorcontrib><creatorcontrib>Bodí, M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vilarrasa, L Canadell</au><au>Broseta, PA López</au><au>Parada, L Sánchez</au><au>Marqués, M Martín</au><au>López, A de Dios</au><au>Sirgo, G</au><au>Rodriguez, A</au><au>Esteban, F</au><au>Olona, M</au><au>Bodí, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PS-068 Analysis and improvement of prescription and administration in hospital transitions</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2017-03</date><risdate>2017</risdate><volume>24</volume><issue>Suppl 1</issue><spage>A257</spage><epage>A257</epage><pages>A257-A257</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundAnticholinergic drugs (AchD) are often prescribed in elderly patients. They may increase cognitive and functional disorders, decrease the effects of anticholinesterase drugs (AcsD) and cause other adverse reactions, especially in Alzheimer’s disease (AD).PurposeTo analyse atropinic burden (AB) using various scales in order to quantify the associated risk and to identify the most prescribed AchD in hospitalised patients with AD.Material and methodsBibliographic search in Pubmed using as the main terms ‘atropinic’, ‘anticholinergic’ and ‘Alzheimer’. This was a retrospective study performed from May 2015 to July 2016. APD prescription software and DIRAYA database were used to obtain prescription, demographic and patient data. 9 scales (7 of them validated) were chosen to identify drugs with AB and to quantify them.Results49 hospitalised patients were studied, 26 men and 23 women, with an average age of 81.82±7.13 years. There were 6 deaths during hospitalisation (12.25%). All patients were receiving 1 or more AcsD to treat AD. 4 patients (8%) were not receiving AchD during hospitalisation while the rest were taking 1 or more AchD: 16 patients 1 drug (32.65%), 19 patients 2 drugs (38.77%), 5 patients 3 drugs (10.20%) and 3 patients were taking 4 AchD (6.12%). Only 1 patient was not at risk, 4 were at intermediate–low risk and 44 were at high risk according at least to 1 scale (89.79%). 28 patients were at high risk in 5 or more scales (57.14%). Psychotropic drugs with anticholinergic effects were prescribed in 28 patient (57%). Most prescribed drugs were haloperidol (11 patients, 22.45%), quetiapine (14 patients, 28.57%) and ipratropium (7 patients, 14.28%).ConclusionIt is common practice to prescribe AchD in elderly hospitalised patients with AD. Cumulative administration of these drugs makes this fragile type of patients especially vulnerable to anticholinergic adverse effects.References and/or acknowledgementsVillalba-Moreno AM, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr2015;62:1–8.Montrastuc F, et al. Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French pharmacovigilance database. EJC Pharmacology 2015;71./:891–5.Grey SL, et al. Cumulative use of strong anticholinergic medications and incident dementia. JAMA Intern Med 2015;175:401–7.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2017-000640.574</doi></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A257-A257
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2552765279
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Alzheimer's disease
Patients
Prescription drugs
title PS-068 Analysis and improvement of prescription and administration in hospital transitions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A04%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PS-068%E2%80%85Analysis%20and%20improvement%20of%20prescription%20and%20administration%20in%20hospital%20transitions&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Vilarrasa,%20L%20Canadell&rft.date=2017-03&rft.volume=24&rft.issue=Suppl%201&rft.spage=A257&rft.epage=A257&rft.pages=A257-A257&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2017-000640.574&rft_dat=%3Cproquest_bmj_p%3E4317856621%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1873338956&rft_id=info:pmid/&rfr_iscdi=true